BOSTON & LONDON & CAMBRIDGE, U.K.--(BUSINESS WIRE)--Cancer Research UK and Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced a poster presentation at the 2018 Annual Meeting of the American Society of Clinical Oncology held from June 1 – June 5, 2018 in Chicago, Ill. The poster describes their ongoing phase I/IIa clinical trial of BT1718 in patients with advanced solid tumours, which is the first clinical study of a bicyclic peptide.
Details of the presentation, which will be given by Dr. Udai Banerji, Principal Investigator for the Phase I trial, are as follows:
A
Cancer Research UK phase I/IIa trial of BT1718 (a first in class Bicycle
Drug Conjugate) given intravenously in patients with advanced solid
tumours
Session Title: Developmental
Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Time:
June 4, 2018, 8:00 – 11:30 a.m. CT
ABOUT BT1718
BT1718 is a first-in-class Bicycle Toxin
Conjugate being developed by Bicycle Therapeutics that targets Membrane
Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14. This
target has an established role in cell invasion and metastasis, is
linked to poor outcomes and is over expressed in many solid tumours. In
preclinical models, BT1718 has demonstrated promising target-dependent
efficacy and only a subset of the toxicities typically associated with
other highly potent cancer treatments.
Cancer Research UK’s Centre for Drug Development (CDD) is sponsoring a Phase I/IIa study of BT1718 that started in February 2018 with patients currently progressing through dose escalation cohorts. The trial is co-managed by Cancer Research UK and Bicycle Therapeutics. Under the terms of the agreement, Bicycle retains the right to further advance the BT1718 program, at which point an undisclosed payment split between cash and equity, success-based milestones and royalty payments would be made to Cancer Research UK.
ABOUT BICYCLE THERAPEUTICS
Bicycle Therapeutics is
developing a unique class of chemically synthesised medicines based on
its proprietary bicyclic peptide (Bicycle®) product platform to
address therapeutic needs unreachable with existing treatment
modalities. Bicycle’s internal focus is in oncology, where the company
is developing targeted cytotoxics (Bicycle Toxin Conjugates),
targeted innate immune activators and T-cell modulators for cancers of
high unmet medical need. Bicycles’ small size and exquisite
targeting deliver rapid tumour penetration and retention while clearance
rates and routes of elimination can be tuned to minimise exposure of
healthy tissue and bystander toxicities. The company’s lead program,
BT1718, is being evaluated in a Phase I/IIa trial in collaboration with
Cancer Research UK. The company’s unique intellectual property is based
on the work initiated at the MRC Laboratory of Molecular Biology in
Cambridge, U.K., by the scientific founders of the company, Sir Gregory
Winter and Professor Christian Heinis. Bicycle has its headquarters in
Cambridge, U.K., with many key functions and members of its leadership
team located in the biotech hub of Boston, Mass. For more information,
visit www.bicycletherapeutics.com or
follow us on Twitter at @Bicycle_tx.
ABOUT CANCER RESEARCH UK’S COMMERCIAL PARTNERSHIPS TEAM
Cancer
Research UK is the world’s leading cancer charity dedicated to saving
lives through research. Our specialist Commercial Partnerships Team work
closely with leading international cancer scientists and their
institutes to protect intellectual property arising from their research
and to establish links with commercial partners. The team develop
promising ideas into successful cancer therapeutics, software, devices,
diagnostics and enabling technologies. This helps to accelerate progress
in exciting new discoveries in cancer research and bring new treatments
to patients sooner. http://commercial.cancerresearchuk.org/
Cancer Research UK’s commercial activity operates through Cancer Research Technology Ltd. (CRT), a wholly owned subsidiary of Cancer Research UK. It is the legal entity which pursues drug discovery research in themed alliance partnerships and delivers varied commercial partnering arrangements.
ABOUT CANCER RESEARCH UK’S CENTRE FOR DRUG DEVELOPMENT
Cancer
Research UK has an impressive record of developing novel treatments for
cancer. The Cancer Research UK Centre for Drug Development, formerly the
Drug Development Office, has been pioneering the development of new
cancer treatments for 25 years, taking over 140 potential new
anti-cancer agents into clinical trials in patients. It currently has a
portfolio of around 30 new anti-cancer agents in preclinical
development, Phase I or early Phase II clinical trials. Six of these new
agents have made it to market including temozolomide for brain cancer,
abiraterone for prostate cancer and rucaparib for ovarian cancer. Two
other drugs are in late development Phase III trials. This rate of
success is comparable to that of any pharmaceutical company.
ABOUT CANCER RESEARCH UK
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
- Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no funding from the UK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK’s vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK’s work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.